Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University



Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System






Title
Integrative Oncogenomics of Multiple Myeloma
(PI)

SPORE in Multiple Myeloma
(PI)

Molecular Manipulation to Enhance Anti-Myeloma Response
(PI)



Yr Title Project-Sub Proj Pubs
2023 Molecular Manipulation to Enhance Anti-Myeloma Response 2I01BX001584-09
2023 Project 4: Targeting genomic instability and evolution in myeloma 2P01CA155258-11-8233
2023 Integrative Oncogenomics of Multiple Myeloma 2P01CA155258-11
2023 Core 1: Administrative Core 2P01CA155258-11-8234
2023 Tissue Banking Core 5P50CA100707-20-8564
2023 SPORE in Multiple Myeloma 5P50CA100707-20
2023 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-20-8567
2022 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-19-8567
2022 SPORE in Multiple Myeloma 5P50CA100707-19
2022 Tissue Banking Core 5P50CA100707-19-8564
Showing 10 of 95 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, Cifric S, Folino P, Vinaixa D, Barello F, Clericuzio C, Favasuli VK, Maisano D, Talluri S, Prabhala RH, Bianchi G, Fulciniti M, Wen K, Kurata K, Liu J, Penailillo J, Bragoni A, Sapino A, Richardson PG, Chauhan D, Carrasco RD, Hideshima T, Munshi NC, Anderson KC. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024 Mar 29. PMID: 38551812
     
  2. Letouzé E, Moreau P, Munshi NC, Samur MK, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024 Mar 21. PMID: 38513088
     
  3. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Res. 2024 Mar 15; 84(6):936. PMID: 38486489
     
  4. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Retraction: Nuclear Factor-?B p65 Mediates Tumor Necrosis Factor a-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein. Cancer Res. 2024 Mar 15; 84(6):939. PMID: 38486487
     
  5. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC. Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling. Cancer Res. 2024 Mar 15; 84(6):938. PMID: 38486484
     
  6. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC. Retraction: Effects of Oligonucleotide N3'?P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells. Cancer Res. 2024 Mar 15; 84(6):937. PMID: 38486483
     
  7. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line. Cancer Res. 2024 Mar 15; 84(6):940. PMID: 38486482
     
  8. Kumar S, Talluri S, Zhao J, Liao C, Potluri LB, Buon L, Mu S, Shi J, Chakraborty C, Tai YT, Samur MK, Munshi NC, Shammas MA. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma. Blood. 2024 Mar 14; 143(11):996-1005. PMID: 37992230
     
  9. Grasedieck S, Panahi A, Jarvis MC, Borzooee F, Harris RS, Larijani M, Avet-Loiseau H, Samur M, Munshi N, Song K, Rouhi A, Kuchenbauer F. Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier. Leukemia. 2024 Mar 09. PMID: 38461190
     
  10. Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin DB, Livak K, Li S, Tarannum M, Romee R, Samur M, Munshi NC, Kaneko S, Ritz J, Anderson KC. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma. Blood. 2024 Mar 07; 143(10):895-911. PMID: 37890146; PMCID: PMC10940063; DOI: 10.1182/blood.2023020528;
     
Showing 10 of 590 results. Show More